Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
302.70 x 1 310.63 x 1
Post-market by (Cboe BZX)
306.86 -7.52 (-2.39%) 03/25/25 [NASDAQ]
302.70 x 1 310.63 x 1
Post-market 306.94 +0.08 (+0.03%) 18:58 ET
Quote Overview for Tue, Mar 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
303.51
Day High
314.22
Open 313.98
Previous Close 314.38 314.38
Volume 2,565,300 2,565,300
Avg Vol 3,210,955 3,210,955
Stochastic %K 19.53% 19.53%
Weighted Alpha +6.67 +6.67
5-Day Change -11.79 (-3.70%) -11.79 (-3.70%)
52-Week Range 253.30 - 346.85 253.30 - 346.85
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 168,886,528
  • Shares Outstanding, K 537,205
  • Annual Sales, $ 33,424 M
  • Annual Income, $ 4,090 M
  • EBIT $ 7,258 M
  • EBITDA $ 12,850 M
  • 60-Month Beta 0.53
  • Price/Sales 5.08
  • Price/Cash Flow 10.41
  • Price/Book 28.91

Options Overview Details

View History
  • Implied Volatility 22.21% ( +1.29%)
  • Historical Volatility 21.55%
  • IV Percentile 36%
  • IV Rank 10.83%
  • IV High 55.92% on 11/20/24
  • IV Low 18.11% on 05/21/24
  • Put/Call Vol Ratio 1.41
  • Today's Volume 17,539
  • Volume Avg (30-Day) 14,803
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 159,223
  • Open Int (30-Day) 189,554

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.18
  • Number of Estimates 12
  • High Estimate 4.84
  • Low Estimate 3.89
  • Prior Year 3.96
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
303.10 +1.24%
on 02/27/25
Period Open: 315.63
335.88 -8.64%
on 03/10/25
-8.77 (-2.78%)
since 02/25/25
3-Month
257.05 +19.38%
on 01/06/25
Period Open: 264.49
335.88 -8.64%
on 03/10/25
+42.37 (+16.02%)
since 12/24/24
52-Week
253.30 +21.14%
on 12/19/24
Period Open: 280.82
346.85 -11.53%
on 07/25/24
+26.04 (+9.27%)
since 03/25/24

Most Recent Stories

More News
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 87.87 (-4.81%)
REGN : 634.14 (-4.06%)
AMGN : 306.86 (-2.39%)
AXSM : 120.36 (-6.82%)
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame,...

NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
RHHBY : 43.3800 (+1.10%)
AMGN : 306.86 (-2.39%)
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan

Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...

ITCI : 131.70 (unch)
JNJ : 161.02 (-1.39%)
KVUE : 23.10 (-1.16%)
AMGN : 306.86 (-2.39%)
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

SRPT : 73.61 (-3.56%)
BMRN : 71.53 (-0.64%)
GILD : 107.89 (+1.08%)
MRNA : 33.85 (-0.94%)
AMGN : 306.86 (-2.39%)
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...

NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
ABBV : 201.34 (-3.74%)
AMGN : 306.86 (-2.39%)
Prediction: These 2 Stocks Will Outperform the Market Through 2030

Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money...

AMGN : 306.86 (-2.39%)
ISRG : 519.81 (+2.21%)
Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen

It's time for another round of The Market Cap Game Show on Rule Breaker Investing . Remember that market cap calculates a company's value by multiplying share price with shares outstanding, and there's...

NFLX : 997.28 (+2.60%)
META : 626.31 (+1.21%)
GOOGL : 170.56 (+1.72%)
NVDA : 120.69 (-0.59%)
GOOG : 172.79 (+1.68%)
TRIP : 15.33 (+2.13%)
WAL : 80.56 (+0.06%)
RKLB : 20.27 (+0.30%)
OKTA : 116.72 (+0.29%)
CARG : 31.75 (+1.11%)
AMGN : 306.86 (-2.39%)
DIS : 101.61 (+1.43%)
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
AMGN : 306.86 (-2.39%)
Is the MAGA ETF a Good Way to Profit From Trump’s Policies?

There are exchange-traded funds (ETFs) for just about any investing theme these days. One of the best ...

YUM : 155.80 (-0.01%)
MNST : 57.84 (+0.02%)
MAGA : 48.45 (-0.46%)
AMGN : 306.86 (-2.39%)
Is Eli Lilly Stock a Buy?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and...

VKTX : 27.98 (-4.44%)
NVO : 73.60 (-2.30%)
MS : 125.20 (+0.75%)
LLY : 852.35 (-1.45%)
AMGN : 306.86 (-2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 323.59
2nd Resistance Point 318.91
1st Resistance Point 312.88
Last Price 306.86
1st Support Level 302.17
2nd Support Level 297.49
3rd Support Level 291.46

See More

52-Week High 346.85
Fibonacci 61.8% 311.11
Last Price 306.86
Fibonacci 50% 300.08
Fibonacci 38.2% 289.04
52-Week Low 253.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals